No insider purchase over the last 90 days. The latest, by 스타치얼코퍼레이션, was filed 05 Jun 2026.
CQV Co., Ltd.: what insiders have been doing
CQV Co., Ltd. is a Chemicals company. Its directors and officers file their transactions with DART (FSS). The last twelve months, up to 2 November 2026, brought 5 filings signed by 2 insiders.
Every open-market trade in the period is a purchase: 4 purchases worth €293k, from 1 insider, and not a single sale. The totals exclude 3 filings filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 major shareholder. One trade stands out by size: a purchase of €293k from 스타치얼코퍼레이션, disclosed on 2 June 2026, or 1.2% of market capitalisation.
Compared with its exchange (2,655 companies, median 7 filings), a count of 5 filings is below the norm. The full history, which starts in 2021, counts 25 purchases against 2 sales.
The latest purchase dates back some time: it was published 157 days ago, on 5 June 2026. Between a trade and the moment it shows up on DART (FSS), the median delay is 4 days. This delay matters because a trade only becomes useful information once it is public.
Other companies in the same sector with recent insider buying flagged by our signals: Symrise AG and Titan. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -10.1%Entry ₩3,405 · Close 30 Oct 2026 ₩3,060
- -7.5%Entry ₩4,320 · Close at T+90 ₩3,995
- -11.7%Entry ₩4,925 · Close at T+365 ₩4,350
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 100,621 sharesKRXDART:20260605000208Canonical exit: 3 Sept 2026 (T+90)
- 100,621 sharesShareKRXDART:20260605000205Canonical exit: 3 Sept 2026 (T+90)
- 135,599 shares@ ₩3,784.99321.24% mcap100.0% of flowShareKRXDART:20260602000259Canonical exit: 27 Aug 2026 (T+90)
- 135,599 sharesKRXDART:20260602000260Canonical exit: 25 Aug 2026 (T+90)
- ShareKRXDART:20260415000218
- 146,849 sharesKRXDART:20251002000456Canonical exit: 24 Dec 2025 (T+90)
- 146,849 sharesShareKRXDART:20251002000454Canonical exit: 31 Dec 2025 (T+90)
- 296,382 sharesKRXDART:20250926000598Canonical exit: 22 Dec 2025 (T+90)
- 294,058 sharesKRXDART:20250926000120Canonical exit: 22 Dec 2025 (T+90)
- 294,058 sharesShareKRXDART:20250926000116Canonical exit: 25 Dec 2025 (T+90)
- 270,093 sharesKRXDART:20250924000244Canonical exit: 16 Dec 2025 (T+90)
- 270,093 sharesShareKRXDART:20250924000239Canonical exit: 23 Dec 2025 (T+90)
- 123,915 sharesKRXDART:20250710000423Canonical exit: 7 Oct 2025 (T+90)
- 123,915 sharesShareKRXDART:20250710000415Canonical exit: 8 Oct 2025 (T+90)
- 218,800 sharesKRXDART:20250708000053Canonical exit: 29 Sept 2025 (T+90)
- 218,800 sharesShareKRXDART:20250708000044Canonical exit: 6 Oct 2025 (T+90)
- ●Executives0DART
- ●Executives0DART
- ShareKRXDART:20240814001252
- 1,267,361 sharesKRXDART:20240705000350Canonical exit: 26 Sept 2024 (T+90)
- 868,055 sharesKRXDART:20240701000362Canonical exit: 24 Sept 2024 (T+90)
- 23,511 sharesShareKRXDART:20240409002829Canonical exit: 26 Jun 2024 (T+90)
- 86,338 sharesKRXDART:20240409002915Canonical exit: 26 Jun 2024 (T+90)
- 62,567 sharesShareKRXDART:20240409002871Canonical exit: 26 Jun 2024 (T+90)
25 of 37 declarations
About CQV Co., Ltd.
씨큐브 is a company operating in the chemical and materials sector, listed on the XKRX market. It specializes in the development and production of various chemical materials.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
